Daewoong Pharmaceutical Unveils Promising Phase 2 Trial Results for Bersiporocin at ATS 2025 Daewoong Pharmaceutical shared interim results from a Phase 2 trial of Bersiporocin at ATS 2025, noting diverse global patient demographics and efficacy data.

Daewoong Pharmaceutical Unveils Promising Phase 2 Trial Results for Bersiporocin at ATS 2025 #USA #San_Francisco #ATS_2025 #Daewoong #Bersiporocin

Rein Therapeutics Showcases Cutting-Edge Research at ATS 2025 Conference Rein Therapeutics presents groundbreaking research on LTI-03, showcasing its potential for treating idiopathic pulmonary fibrosis at the ATS 2025 conference.

Rein Therapeutics Showcases Cutting-Edge Research at ATS 2025 Conference #USA #Austin #Rein_Therapeutics #LTI-03 #ATS_2025

Rein Therapeutics to Present Groundbreaking Research at ATS 2025 Conference Rein Therapeutics, a biopharmaceutical leader, announces an accepted abstract for presentation on innovative therapies at the ATS 2025 Conference in San Francisco.

Rein Therapeutics to Present Groundbreaking Research at ATS 2025 Conference #United_States #San_Francisco #Rein_Therapeutics #LTI-03 #ATS_2025